John Castle

480 posts

John Castle banner
John Castle

John Castle

@joccastle

Inventing & translating technologies for therapies. ML AI ‘omics & comp biology. Molecular glue for targeted protein degraders. @MonteRosaTx Tweets my own

Mainz, Germany Katılım Kasım 2010
1.3K Takip Edilen796 Takipçiler
John Castle retweetledi
Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics, Inc@MonteRosaTx·
We’re turning scientific insight into meaningful progress for heart health – advancing a new way to treat inflammation in ASCVD by targeting the NLRP3/NEK7 pathway upstream. Our NEK7-directed molecular glue degrader, MRT-8102, is designed to stop NLRP3 activation at the source.
English
0
4
7
425
John Castle retweetledi
Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics, Inc@MonteRosaTx·
Today, we announced updated, positive clinical data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). bit.ly/4u87raO
English
0
2
5
445
John Castle retweetledi
Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics, Inc@MonteRosaTx·
It’s not “just” cholesterol. The role of inflammation in atherosclerotic cardiovascular disease (ASCVD) is gaining increased attention.
English
1
1
2
175
John Castle retweetledi
Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics, Inc@MonteRosaTx·
CMO, Filip Janku, comments on the future clinical plans for MRT-8102 based on the highly encouraging data we have observed so far in our ongoing Phase 1 study. Read the full data release here: bit.ly/4pxGtWz
Monte Rosa Therapeutics, Inc tweet media
English
0
2
3
256
John Castle retweetledi
Zavain Dar
Zavain Dar@zavaindar·
congrats @MonteRosaTx ($GLUE) on this morning's stunning data from MRT-8102, showing potent NEK7 degradation and potential best in class removal of hsCRP in a daily oral format. this is a potential game changer for ASCVD
Zavain Dar tweet mediaZavain Dar tweet media
Zavain Dar@zavaindar

Dimension has co-led a $100M financing into @MonteRosaTx. Thrilled to support @markus_warmuth and the entire team at the cutting edges of geometric deep learning, next gen proteomics, and molecular glue degraders.

English
2
6
54
14.6K
John Castle retweetledi
Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics, Inc@MonteRosaTx·
Today, we reported positive interim data from an ongoing Phase 1 study of MRT-8102. We believe these data support the potential of MRT-8102 to be an oral best-in-class therapeutic among agents targeting the NRLP3/IL-1/IL-6 pathway. bit.ly/4pxGtWz
Monte Rosa Therapeutics, Inc tweet media
English
0
1
4
326
John Castle retweetledi
Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics, Inc@MonteRosaTx·
Today, we announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6.
English
1
2
9
4K
John Castle retweetledi
Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics, Inc@MonteRosaTx·
Through proteomic profiling of our proprietary compound library, our team identified a selective, fast, and potent molecular glue degrader that induces cereblon degradation via a novel mechanism. Read the full paper in @NatureComms: rdcu.be/eQKQk
English
0
1
2
368
John Castle retweetledi
Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics, Inc@MonteRosaTx·
Today we announced our second collaboration with @Novartis to develop novel degraders for immune-mediated diseases. Given the strong progress we’ve made on our collaboration advancing VAV1 degraders, we’re thrilled to be collaborating with them again: bit.ly/4piSOyN
Monte Rosa Therapeutics, Inc tweet media
English
2
2
12
2.4K
John Castle retweetledi
Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics, Inc@MonteRosaTx·
Thanks to Alex Eccleston of Nature Reviews Drug Discovery for a very nice summary of our recent Science Magazine publication. If you don’t have time to read the full paper, make the time! Or read this summary, which provides a great overview. nature.com/articles/d4157…
Monte Rosa Therapeutics, Inc tweet media
English
0
2
6
520
John Castle retweetledi
BiotechTV
BiotechTV@BiotechTV·
𝐁𝐞𝐡𝐢𝐧𝐝 𝐭𝐡𝐞 𝐒𝐜𝐞𝐧𝐞𝐬: BiotechTV visited @MonteRosaTx in Boston, MA yesterday and learned about the work they are doing on molecular glue degraders. Scientist Katherine Jones showed us some of the equipment that makes it happen.
English
0
2
12
2K
John Castle retweetledi
BiotechTV
BiotechTV@BiotechTV·
𝐂𝐨𝐦𝐢𝐧𝐠 𝐒𝐨𝐨𝐧: BiotechTV visited @MonteRosaTx in Boston today and spoke with @markus_warmuth about the latest in molecular glue degraders. Watch for the full episode later this afternoon.
English
0
2
20
5K
John Castle retweetledi
Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics, Inc@MonteRosaTx·
We’re excited to announce the first subjects have been dosed in a Phase 1 study of MRT-8102, a NEK7-directed MGD being developed for inflammatory conditions linked to the NLRP3 inflammasome, IL-1β, and IL-6. Learn more: bit.ly/4m5JOe7
English
1
2
9
1.1K
John Castle retweetledi
Markus Warmuth
Markus Warmuth@markus_warmuth·
40yrs LiveAid! 40 years ago at 6.41pm Queen came on stage for their legendary performance! When we had to name our @MonteRosaTx product engine we wanted it to represent greatness and doing the impossible. So we picked QuEEN! Best choice ever! Aye-Oh!
Markus Warmuth tweet media
English
1
1
7
291
John Castle retweetledi
Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics, Inc@MonteRosaTx·
We’ve shown the molecular glue target space is broader than previously understood and we believe we're uniquely positioned to harness its potential: bit.ly/4koxZ1m
English
0
1
2
265

Keşfet

@markus_warmuth @MonteRosaTx @NatureComms @Novartis @ScienceMagazine @elonmusk @BarackObama @taylorswift13